MOMichael Hecht Olsen

Michael Hecht Olsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Hecht Olsen has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial

    by Anna Meta Dyrvig Kristensen, Therese Lucia Friis Holmager, Frida Rykind-Eriksen, Morten Wang Fagerland, Sigrun Halvorsen, Michael Hecht Olsen, Arnhild Bakken, Dan Atar, John Munkhaugen, Eva Prescott

    Aims: The effect of beta-blockers initiated after myocardial infarction (MI) on subsequent angina burden remains uncertain. Methods and results: This pre-specified BETAMI-DANBLOCK substudy included patients with MI and left ventricular ejection fraction (LVEF)≥40% randomized to beta-blockers or no beta-blockers. Endpoints comprised angina-related hospital contacts/diagnostic ischemia tests, coronary revascularization, anti-anginal medications (≥2 prescriptions for calcium-channel blockers/nitrates), and patient-reported angina symptoms [Canadian Cardiovascular Society (CCS) class 0-4]. Subdistribution hazard ratios (SHR) were estimated by Fine-Gray models. Anti-anginal prescriptions were compared using 95% confidence intervals (CI) for differences in proportions. A total of 5574 patients were randomized to beta-blockers (n=2783, median dose 50 mg metoprolol) or no beta-blockers (n=2791). During median 3.5 years follow-up, an angina-related hospital contact/diagnostic ischemia test occurred in 724 patients (26.0%) in the beta-blocker group vs. 834 (29.9%) in the no beta-blocker group (SHR 0.85; 95% CI, 0.77-0.94). Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)(SHR 0.99; 95% CI 0.76-1.29). Fewer patients in the beta-blocker group were treated with calcium-channel blockers [630(22.7%) vs. 738(26.6%); -3.9 percentage points (95% CI, -6.2 to -1.6)], whereas nitrate use [342(12.3%) vs. 356(12.8%); -0.5 (95% CI, -2.2 to 1.2)] and CCS-scores were similar between groups (difference in change at 12-months, -0.04; 95% CI, -0.14-0.05). Conclusions: In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.

  • Low-grade inflammation predicts major cardiovascular events and mortality in recently diagnosed type 2 diabetes: a Danish nationwide cohort study

    by Sidsel L Domazet, Alaa Sharfo, Thomas B Olesen, Jacob V Stidsen, Jens S Nielsen, Reimar W Thomsen, Niels Jessen, Peter Vestergaard, Mette K Andersen, Torben Hansen, et al.

    Aims: This study aimed to investigate the prospective associations of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hsCRP) levels with major adverse cardiac event (MACE) and mortality in individuals recently diagnosed with type 2 diabetes and without prevalent cardiovascular disease (CVD). Methods and results: We included 7630 individuals recently diagnosed with type 2 diabetes (median duration 0.9 years) with a median age of 60 years (44% females). Individuals with prevalent CVD (n = 1390) were excluded from the primary analyses modelling Fine-Gray subdistribution hazard regressions accounting for competing risk of non-CVD death and adjusting for classical risk factors (e.g. diabetes duration, smoking, alcohol, physical activity, waist circumference, LDL cholesterol, haemoglobin A1c, systolic blood pressure, estimated glomerular filtration rate, and pharmacological treatment). Subsequently, we evaluated the predictive ability of adding low-grade inflammation to a model containing classical risk factors. Median follow-up time was 9 years. A 1-SD increase in log-IL-6 (1.98 pg/mL), log-TNF-α (1.40 pg/mL) and log-hsCRP (3.28 mg/L) was associated with HRs of 1.16 (95% CI 1.09, 1.23), 1.01 (0.95, 1.08), and 1.16 (1.09, 1.25) for MACE and 1.38 (1.31, 1.45), 1.16 (1.10, 1.22), and 1.34 (1.25, 1.43) for all-cause mortality, respectively. Prediction of both MACE and all-cause mortality was slightly improved by adding IL-6 and hsCRP to the model alongside classical risk factors. Conclusion: Low-grade inflammation was associated with MACE and all-cause mortality, independently of classical risk factors, in individuals recently diagnosed with type 2 diabetes and without prevalent CVD. Despite improved predictive ability of IL-6 and hsCRP, the absolute improvement was sparse. Lay Summary: Higher levels of chronic inflammation were associated with a higher risk of cardiovascular disease and mortality in individuals recently diagnosed with type 2 diabetes and without known cardiovascular disease.Especially, IL-6 and hsCRP were associated with a higher risk of myocardial infarction, ischaemic stroke, coronary revascularization, and heart failure hospitalizationOverall, chronic inflammation was a better predictor of mortality than non-fatal cardiovascular events


  • Open Access

    Elevated Fracture Risk in a Danish Cohort with Type 2 Diabetes Mellitus and Microvascular Diseases

    by Mohamad I Nasser, Therese K Grønborg, Frederik P B Kristensen, Reimar W Thomsen, Allan Vaag, Jens Steen Nielsen, Kurt Højlund, Michael H Olsen, Peter Vestergaard, Richard Eastell, et al.

    Microvascular diseases (MVD) in type 2 diabetes mellitus (T2D) are associated with alterations in the bone microarchitecture, but their association with fracture risk is unclear. We investigated whether MVD (retinopathy, nephropathy, and neuropathy) are associated with higher fracture risk in persons with T2D. We identified 10491 persons with T2D, enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes cohort between 2010 and 2022. The primary outcomes were any hospital-diagnosed fracture (except facial and cranial), and major osteoporotic fractures (MOF), defined as clinical vertebral, hip, humerus, and forearm fractures, in persons with hospital-diagnosed MVD versus without MVD. We used Cox proportional hazard models to calculate crude and adjusted hazard ratios (aHRs). During a median follow-up of 7.6 years IQR (3.5; 9.7), the rates of any fracture were higher in persons with T2D and MVD versus no MVD (aHR 1.31; 95% CI [1.15; 1.51]). Similarly, MOF rate was elevated in persons with MVD (aHR 1.33 [1.09; 161]). The rates for any fracture and MOF were highest in persons with neuropathy (aHR 1.49 [1.24; 1.78] and aHR 1.54 [1.19; 1.99], respectively). Fracture risk is elevated in persons with T2D complicated by MVD, particularly in those with neuropathy.

  • Open Access

    Associations Between Neuropathy, Nephropathy and Hearing Loss in Individuals with Type 2 Diabetes

    by Joutiar Razay, Jesper Hvass Schmidt, Mette K. Andersen, Jens S. Nielsen, Michael Hecht Olsen, Thomas Bastholm Olesen

    Aims: The aim of this study was to investigate the associations between symptomatic hearing loss (HL), neuropathy, and nephropathy in subjects with Type 2 diabetes mellitus (T2DM). Furthermore, the study evaluated whether HL was associated with chronic low-grade inflammation, assessed based on plasma levels of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP), and explored potential sex-specific differences. Materials and Methods: We included 4245 subjects with T2DM from The Danish Centre for Strategic Research in Type 2 Diabetes cohort. Symptomatic HL was defined using ICD-10 codes. In 2016, a questionnaire was sent out to evaluate neuropathy using the Michigan Neuropathy Screening Instrument (MNSI ≥ 4). Nephropathy was defined as urinary albumin-to-creatinine ratio (UACR) >30 mg/g. Plasma levels of TNF-α, IL-6, and hsCRP were measured at enrolment from 2010 to 2016. Multivariable logistic regression was used, adjusting for covariates. Results: Neuropathy was significantly associated with HL (OR = 1.83, 95%CI [1.42, 2.35], p < 0.001), and the association was stronger in women (OR = 2.74 [1.81, 4.14], p < 0.001) compared to men (OR = 1.44 [1.04, 1.99], p < 0.05) (P-interaction = 0.020). No significant association was found between nephropathy and HL. Among inflammatory markers, only the highest tertile of TNF-α levels was significantly associated with HL compared to the lowest tertile (OR = 1.40 [1.07, 1.82], p < 0.05) without any sex interaction. Conclusions: In subjects with T2DM, neuropathy was associated with symptomatic HL, and the association seemed to be stronger in females. Among chronic low-grade inflammation markers, only TNF-α was significantly associated with symptomatic HL. Additionally, no significant association was found between nephropathy and HL.


  • Open Access

    The temporal interplay between physical activity, emotional well-being, and health-related quality of life in individuals with recently diagnosed type 2 diabetes mellitus: a cross-lagged panel analysis

    by Sofie Frigaard Kristoffersen, Sidsel Louise Domazet, Frans Pouwer, Jens Steen Nielsen, Thomas Bastholm Olesen, Jacob Volmer Stidsen, Michael Hecht Olsen, Kurt Højlund


  • Open Access

    Building Scientific Writing and Publication Capacity of New Authors from Low- and Middle-Income Countries: A Multicomponent Global Collaboration Model

    by Qaiser Mukhtar, Sushama D. Acharya, Andrew E. Moran, Daniel T. Lackland, Carl Reddy, Dinesh Neupane, Elizabeth Krajan Pardo, Birgit Bolton, Patricia Richter, Michael H. Olsen

    Peer-reviewed publications using local data are critical for understanding disease burdens, generating evidence, and shaping policies tailored to community needs. Although low- and middle-income countries (LMICs) account for 80% of cardiovascular disease (CVD) deaths, they contribute only 2.8% of CVD publications. To address this gap, the US Centers for Disease Control and Prevention (CDC) and partners launched the Emerging Authors Program for Global Cardiovascular Research (EAP), supporting early- to mid-career LMIC practitioners. EAP coordinated mentorship, provided virtual writing tools, training, technical support, and financial assistance for open access. Between 2019 and 2023, three waves engaged 33 authors from 11 countries, resulting in 31 published manuscripts in six journals, with support from 23 global mentors. The success was driven by committed mentors, motivated authors, local collaboration, accessible resources, and strong communication. Strengthening LMIC authors’ writing and publication skills is essential for advancing rigorous research and global health equity in scientific publishing.


  • Open Access

    Influence of Multiple Risk Factor Management on the Onset and Progression of Chronic Kidney Disease in Patients With Hypertension

    by Xinyi Peng, Shuohua Chen, Shouling Wu, Xiong Ding, Kuangyi Wu, Zhe Huang, Qirui Song, Yang Liu, Maoxiang Zhao, Michael Hecht Olsen, et al.

    Background: Patients with hypertension face a significantly elevated risk of renal dysfunction. However, whether this risk can be mitigated by joint risk factor control remains uncertain. Methods: Using Cox proportional hazards models, this study investigated the association between the number of controlled baseline risk factors (systolic blood pressure, low‐density lipoprotein cholesterol, fasting blood glucose, and body mass index) and the development and progression of chronic kidney disease. Results: We analyzed 77 356 participants with hypertension and 1:1 age‐ and sex‐matched counterparts without hypertension for incident chronic kidney disease over a median follow‐up of 13.40 years. Among participants with hypertension, each additional controlled risk factor was associated with an 18% lower risk of chronic kidney disease (hazard ratio [HR], 0.82 [95% CI, 0.81–0.84]), and controlling all 4 factors (versus ≤1) reduced the risk by 42% (HR, 0.58 [95% CI, 0.52–0.63]). Effective multifactorial management progressively narrowed the risk gap between hypertensive and normotensive individuals. Chronic kidney disease progression was assessed in 9543 participants with hypertension and 6799 participants without hypertension over 11.88 years. Each additional controlled risk factor was associated with an 18% lower progression risk (HR, 0.82 [95% CI, 0.78–0.86]). Controlling 3 factors was sufficient to eliminate the excess progression risk between groups with hypertension and groups without hypertension, while controlling all 4 factors lowered the risk by 31% (HR, 0.69 [95% CI, 0.53–0.89]). Conclusions: This study demonstrates a clear dose–response relationship between the number of controlled risk factors and the magnitude of kidney risk reduction. A comprehensive, multifactorial control strategy can progressively reduce and potentially normalize the excess kidney risk in hypertensive individuals. These findings support a more quantitative and stage‐specific approach to hypertension management.


  • Open Access

    Protocol for the Digital, Individualized, and Collaborative Treatment of Type 2 Diabetes in General Practice Based on Decision Aid (DICTA)—A Randomized Controlled Trial

    by Sofie Frigaard Kristoffersen, Jeanette Reffstrup Christensen, Louise Munk Ramo Jeremiassen, Lea Bolette Kylkjær, Nanna Reffstrup Christensen, Sally Wullf Jørgensen, Jette Kolding Kristensen, Sonja Wehberg, Ilan Esra Raymond, Dorte E. Jarbøl, et al.

    Background: Despite significant advancements in diabetes care, many individuals with type 2 diabetes (T2D) do not receive optimal care and treatment. Digital interventions promoting behavioral changes have shown promising long-term results in supporting healthier lifestyles but are not implemented in most healthcare offerings, maybe due to lack of general practice support and collaboration. This study evaluates the efficacy of the Digital, Individualized, and Collaborative Treatment of T2D in General Practice Based on Decision Aid (DICTA), a randomized controlled trial integrating a patient-centered smartphone application for lifestyle support in conjunction with a clinical decision support (CDS) tool to assist general practitioners (GPs) in optimizing antidiabetic treatment. Methods: The present randomized controlled trial aims to recruit 400 individuals with T2D from approximately 70 GP clinics (GPCs) in Denmark. The GPCs will be cluster-randomized in a 2:3 ratio to intervention or control groups. The intervention group will receive one year of individualized eHealth lifestyle coaching via a smartphone application, guided by patient-reported outcomes (PROs). Alongside this, the GPCs will have access to the CDS tool to optimize pharmacological decision-making through electronic health records. The control group will receive usual care for one year, followed by the same intervention in the second year. Results: The primary outcome is the one-year change in estimated ten-year cardiovascular risk, assessed by SCORE2-Diabetes calculated from age, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, age at diabetes diagnosis, HbA1c, and eGFR. Conclusions: If effective, DICTA could offer a scalable, digital-first approach for improving T2D management in primary care by combining patient-centered lifestyle coaching with real-time pharmacological clinical decision support.

  • Open Access

    Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohort

    by Aleksander L. Hansen, Christian F. Christiansen, Charlotte Brøns, Leonie M. Engelhard, Torben Hansen, Jens S. Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H. Olsen, et al.

    Aims/hypothesis: Low birthweight (LBW) is associated with younger age, less obesity and more hypertension among people recently diagnosed with type 2 diabetes, as well as increased cardiovascular morbidity and mortality risk. It is not known whether LBW is associated with an increased risk of incident chronic kidney disease (CKD) among people with a type 2 diabetes diagnosis. Methods: Original midwife records were retrieved for 5982 participants with recently diagnosed type 2 diabetes enrolled in the Danish Center for Strategic Research in Type 2 Diabetes (DD2) cohort between 2010 and 2024. They were followed until first incident CKD diagnosis, defined as either two eGFR measurements 3 mg/mmol, each 90–365 days apart. Confounder-standardised 10 year risks of CKD were estimated, with death considered as a competing risk. Adjusted hazard ratios (aHRs) for CKD were computed using Cox and spline regression analyses. All analyses were controlled for differences in sex, age at enrolment, calendar year at birth, family history of diabetes and born-at-term status. Mixed-effects models were used to examine the trajectories of eGFR and UACR following enrolment. Results: A total of 1501 incident CKD endpoints occurred, corresponding to an incidence rate of 42.4 per 1000 person-years over a median follow-up time of 8.3 years. Spline models with birthweight as a continuous measure showed progressively increasing aHRs for CKD with decreasing birthweight. The 10-year standardised risk of CKD was 36.0% in people with LBW (4000 g) had a similar 10-year standardised CKD risk compared with normal birthweight (33.1% and 30.6%, respectively). This yielded an RD of 2.5% (95% CI −1.6%, 6.7%) and an aHR of 1.10 (95% CI 0.93, 1.29). In mixed-effects models examining eGFR and UACR trajectories, each 1 kg decrease in birthweight was associated with a 6.6% (95% CI 1.9, 11.1) increase in UACR, whereas no association was found for eGFR. Conclusions/interpretation: A history of LBW was associated with elevated risk of CKD among people with a recent type 2 diabetes diagnosis, although the precision of risk estimates was limited. Graphical


  • Open Access

    Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes

    by Aleksander L. Hansen, Mette K. Andersen, Leonie M. Engelhard, Charlotte Brøns, Torben Hansen, Jens S. Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H. Olsen, et al.

    Aims: TCF7L2 rs7903146 is the most impactful single genetic risk variant for type 2 diabetes. However, its role on disease progression, complications and mortality among people with type 2 diabetes at diagnosis remains unclear. Materials and Methods: We assessed the per allele impact of the rs7903146 T‐allele on clinical characteristics and complication risk in 9231 individuals with type 2 diabetes at diagnosis and over a 10‐year follow‐up period. Log‐binomial and robust Poisson regression analyses were used to estimate prevalence ratios for clinical characteristics and macro‐ and microvascular complications at diabetes onset, while Cox regression was applied to estimate the risk of complications post‐diagnosis. Analyses were adjusted for sex, calendar year at birth, age at enrollment and diabetes duration. Results: The per T‐allele impact was associated with 0.6 kg/m 2 (95% CI: 0.4, 0.8) lower BMI, 1.4 cm (95% CI: 1.0, 1.8) smaller waist circumference, 5.6% (95% CI: 4.2, 7.0) lower insulin secretion and 5.0% (95% CI: 3.3, 6.7) higher insulin sensitivity. Over 10 years, the per T‐allele impact was associated with lower risks for major adverse cardiovascular events (0.87 [95% CI 0.79, 0.95]), myocardial infarction (0.82 [95% CI: 0.72, 0.93]) and heart failure (0.85 [95% CI 0.73, 1.00]), with no significant impact on microvascular complications. Conclusions: The TCF7L2 variant is associated with less obesity, lower insulin secretion and higher insulin action at diabetes onset, and decreased risk of cardiovascular events following type 2 diabetes onset.